GENE ONLINE|News &
Opinion
Blog

2018-08-15| R&DTechnology

Transposon sheds light on genes associated with developmental brain diseases

by GeneOnline
Share To

The Laboratory of Neural Development and Stem Cell Research at the National Yang-Ming University identified 33 candidate genes associated with developmental brain diseases by screening transposon-mediated somatic mutagenesis. The study of this innovative genetic screening method and clinical discovery was published on Nature Communications.

By Joanne Shih

Many studies have proved that pediatric brain dysfunctions are associated with genetic mutations. Genetic mutations involved in the normal migration and function of cortical neurons often lead to developmental brain disorder, as known as malformations of cortical development (MCDs). MCDs can tremendously affect brain and neurological function, and often result in disorders such as autism, epilepsy, intellectual disability, developmental delay, microcephaly (small brain), and macrocephaly (large brain). However, many causal mutations involved in cortical development remain unknown.

Dr. Jin-Wu Tsai, principle investigator and associate professor at the Institute of Brain Science at National Yang-Ming University. Image source/National Yang-Ming University
Dr. Jin-Wu Tsai, principle investigator and associate professor at the Institute of Brain Science at National Yang-Ming University. Image source/National Yang-Ming University

“It is very difficult to identify genetic mutations causing developmental brain diseases, because most mutations happen in brain and it is hard to screen through every single gene” said Dr. Jin-Wu Tsai, the principle investigator and associate professor at the Institute of Brain Science at National Yang-Ming University. Inspired by Nobel laureate Dr. Barbara McClintock’s research in transposons, also known as “jumping genes”, Dr. Tsai and his team invented an in vivo genetic screening method based on transposon-mediated somatic mutagenesis.

In addition to developing the innovative screening method which can greatly shorten the time required for detecting mutant genes, Tsai’s team took a step forward to find out the clinical relevance of these 33 candidate genes associated with MCDs. They analyzed somatic mutations in brain tissue from patients with related disorders, and as a result they found that gene mutations are enriched in these identified candidate genes.

The research team has been collaborating with Taipei Veterans General Hospital, and helped pediatricians to screen and select treatment for patients with pediatric epilepsy. The new screening method and clinical finding are fundamental to developing potential indicators for early detection, diagnosis, and treatment for brain diseases.

Reference

  1. Lu IL, Chen C, Tung CY, et al. Identification of genes associated with cortical malformation using a transposon-mediated somatic mutagenesis screen in mice. Nat Commun. 2018 Jun 27;9(1):2498. doi: 10.1038/s41467-018-04880-8
  2. Institute of Brain Science, National Yang-Ming University
  3. The Laboratory of Neural Development and Stem Cell Research
  4. http://www.bcc.com.tw/newsView.3120953
  5. https://www.youtube.com/watch?v=fmPM2eIOPjg

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Unveiling the Genetic Links to Dietary Preferences: A Milestone in Precision Nutrition
2023-07-26
R&D
3D Printed Brain Model Could Aid in Neurosurgery
2023-03-31
Avian Flu H5N1: Fear Over Potential Spread Among Humans and What We Should Know
2023-02-15
LATEST
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
2024-02-21
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
2024-02-21
USC-Led Study Reveals Benefits of Fasting-Mimicking Diet in Reducing Disease Risk and Slowing Aging
2024-02-21
Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro
2024-02-21
Targeted Cancer Therapy Breakthrough: Degrader-Antibody Conjugates (DACs) Advance to Clinical Trials
2024-02-19
Degrader-Antibody Conjugates (DACs): Targeted Degradation for Therapeutics
2024-02-19
EVENT
Scroll to Top